Is the current use of 'positivity' thresholds meaningful for evaluating HIV-vaccine immunogenicity endpoints?

AIDS. 2013 May 15;27(8):1362-5. doi: 10.1097/QAD.0b013e328360d52e.
No abstract available

MeSH terms

  • AIDS Vaccines / immunology*
  • Clinical Trials as Topic
  • HIV Infections / immunology*
  • HIV Infections / prevention & control
  • HIV-1 / immunology*
  • Humans
  • Predictive Value of Tests
  • Reproducibility of Results
  • Viral Load

Substances

  • AIDS Vaccines